Search

Displaying results 811 - 820 of 3180 in total
  1. Drug

    Cinnamyl alcohol

    go.drugbank.com/drugs/DB14186
    Approved

    Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test.

  2. Drug

    Indigotindisulfonic acid

    go.drugbank.com/drugs/DB11577
    ApprovedInvestigational

    This compound is an acid-base indicator and is used in the production of food colorants and pH tests.

  3. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) i...

  4. Drug

    Diphenidol

    go.drugbank.com/drugs/DB01231
    ApprovedWithdrawn

    Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.

  5. Drug

    Digitoxin

    go.drugbank.com/drugs/DB01396
    ApprovedWithdrawn

    A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    PF-4191834

    go.drugbank.com/drugs/DB11645
    Investigational

    PF-4191834 has been investigated for the basic science of Asthma.

  7. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  8. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  9. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    PF-03758309

    go.drugbank.com/drugs/DB11775
    Investigational

    PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.

    Salts: Pf 03758309 Hydrochloride